Hypoxic Culture Maintains Cell Growth of the Primary Human Valve Interstitial Cells with Stemness.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
29 Sep 2021
Historique:
received: 31 08 2021
revised: 17 09 2021
accepted: 26 09 2021
entrez: 13 10 2021
pubmed: 14 10 2021
medline: 28 10 2021
Statut: epublish

Résumé

The characterization of aortic valve interstitial cells (VICs) cultured under optimal conditions is essential for understanding the molecular mechanisms underlying aortic valve stenosis. Here, we propose 2% hypoxia as an optimum VIC culture condition. Leaflets harvested from patients with aortic valve regurgitation were digested using collagenase and VICs were cultured under the 2% hypoxic condition. A significant increase in VIC growth was observed in 2% hypoxia (hypo-VICs), compared to normoxia (normo-VICs). RNA-sequencing revealed that downregulation of oxidative stress-marker genes (such as superoxide dismutase) and upregulation of cell cycle accelerators (such as cyclins) occurred in hypo-VICs. Accumulation of reactive oxygen species was observed in normo-VICs, indicating that low oxygen tension can avoid oxidative stress with cell-cycle arrest. Further mRNA quantifications revealed significant upregulation of several mesenchymal and hematopoietic progenitor markers, including CD34, in hypo-VICs. The stemness of hypo-VICs was confirmed using osteoblast differentiation assays, indicating that hypoxic culture is beneficial for maintaining growth and stemness, as well as for avoiding senescence via oxidative stress. The availability of hypoxic culture was also demonstrated in the molecular screening using proteomics. Therefore, hypoxic culture can be helpful for the identification of therapeutic targets and the evaluation of VIC molecular functions in vitro.

Identifiants

pubmed: 34638873
pii: ijms221910534
doi: 10.3390/ijms221910534
pmc: PMC8508607
pii:
doi:

Substances chimiques

Antigens, CD34 0
RNA, Messenger 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Ministry of Education, Culture, Sports, Science and Technology
ID : 18K16396, 16K10631, 19H03740, 19K17603, 19K08585, and 16K109503
Organisme : Public Trust Cardiovascular Research Foundation
ID : 2017
Organisme : Takeda Science Foundation
ID : 2016 and 2020
Organisme : SENSHIN Medical Research Foundation
ID : 2016 and 2020
Organisme : MSD Life Science Foundation, Public Interest Incorporated Foundation
ID : 2016

Références

Biochem Biophys Res Commun. 2013 Nov 1;440(4):780-5
pubmed: 24120498
Exp Cell Res. 2011 Jul 1;317(11):1541-7
pubmed: 21376036
Bone. 1992;13(1):81-8
pubmed: 1581112
J Cell Physiol. 2006 Jul;208(1):64-76
pubmed: 16557516
J Cell Mol Med. 2014 Jan;18(1):104-14
pubmed: 24188055
Cell Commun Signal. 2020 Nov 30;18(1):188
pubmed: 33256735
J Mol Cell Cardiol. 2009 Dec;47(6):828-34
pubmed: 19695258
Cell Transplant. 2010;19(3):279-89
pubmed: 19995482
Circ Res. 2008 Jan 4;102(1):77-85
pubmed: 17967785
Biochem Biophys Res Commun. 2004 Jan 30;314(1):197-207
pubmed: 14715266
Biophys J. 2001 Aug;81(2):675-84
pubmed: 11463616
Cell. 2008 May 16;133(4):704-15
pubmed: 18485877
Ann Thorac Surg. 2020 Jul;110(1):40-49
pubmed: 31760051
Int J Mol Sci. 2020 Aug 31;21(17):
pubmed: 32878299
Circulation. 2001 Mar 20;103(11):1522-8
pubmed: 11257079
Tumour Biol. 2016 Sep;37(9):11611-11622
pubmed: 27337957
Cell Prolif. 2012 Jun;45(3):225-38
pubmed: 22507457
Am J Pathol. 2009 Mar;174(3):1109-19
pubmed: 19218344
Surgery. 2017 Jun;161(6):1525-1535
pubmed: 28143660
Am J Transl Res. 2017 Mar 15;9(3):1521-1529
pubmed: 28386377
Arterioscler Thromb Vasc Biol. 2014 Nov;34(11):2387-93
pubmed: 25189570
Int Heart J. 2016;57(1):104-11
pubmed: 26742884
Science. 1999 Apr 2;284(5411):143-7
pubmed: 10102814
Cytotherapy. 2008;10(3):243-53
pubmed: 18418770
Cell Tissue Res. 2003 Feb;311(2):227-37
pubmed: 12596042
Trends Mol Med. 2018 Oct;24(10):871-885
pubmed: 30153969
Cardiovasc Pathol. 2016 Jan-Feb;25(1):18-24
pubmed: 26386747
Blood. 2011 Jan 13;117(2):459-69
pubmed: 20952688
PLoS One. 2015 Oct 14;10(10):e0139890
pubmed: 26465938
Stem Cells. 2006 Apr;24(4):928-35
pubmed: 16306150
J Dermatol Sci. 2016 May;82(2):84-94
pubmed: 26867959
PLoS One. 2013;8(3):e59354
pubmed: 23555021
J Cell Mol Med. 2014 May;18(5):759-65
pubmed: 24674389
Biophys J. 2001 Aug;81(2):685-96
pubmed: 11463617
Lancet. 2006 Sep 16;368(9540):1005-11
pubmed: 16980116
Circulation. 2003 May 6;107(17):2181-4
pubmed: 12719282
Biomed Pharmacother. 2018 Sep;105:1-9
pubmed: 29807229
Front Cardiovasc Med. 2018 Mar 26;5:27
pubmed: 29632866
Front Cardiovasc Med. 2021 Apr 23;8:639740
pubmed: 33969008
Free Radic Biol Med. 2001 Aug 15;31(4):509-19
pubmed: 11498284
J Proteome Res. 2012 Mar 2;11(3):1537-50
pubmed: 22276806

Auteurs

Kaho Kanno (K)

Department of Cardiovascular and Thoracic Surgery, Ehime University Graduate School of Medicine, Toon, Shitsukawa, Ehime 791-0295, Japan.

Tomohisa Sakaue (T)

Department of Cardiovascular and Thoracic Surgery, Ehime University Graduate School of Medicine, Toon, Shitsukawa, Ehime 791-0295, Japan.
Department of Cell Growth and Tumor Regulation, Proteo-Science Center (PROS), Ehime University, Toon, Shitsukawa, Ehime 791-0295, Japan.

Mika Hamaguchi (M)

Department of Cardiology, Pulmonology, Hypertension, and Nephrology, Ehime University Graduate School of Medicine, Toon, Shitsukawa, Ehime 791-0295, Japan.

Kenji Namiguchi (K)

Department of Cardiovascular and Thoracic Surgery, Ehime University Graduate School of Medicine, Toon, Shitsukawa, Ehime 791-0295, Japan.

Daisuke Nanba (D)

Department of Stem Cell Biology, Medical Research Institute, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo 113-8510, Japan.

Jun Aono (J)

Department of Cardiology, Pulmonology, Hypertension, and Nephrology, Ehime University Graduate School of Medicine, Toon, Shitsukawa, Ehime 791-0295, Japan.

Mie Kurata (M)

Department of Pathology, Division of Analytical Pathology, Ehime University Graduate School of Medicine, Toon, Shitsukawa, Ehime 791-0295, Japan.
Department of Pathology, Proteo-Science Center (PROS), Toon Shitsukawa, Ehime 791-0295, Japan.

Junya Masumoto (J)

Department of Pathology, Division of Analytical Pathology, Ehime University Graduate School of Medicine, Toon, Shitsukawa, Ehime 791-0295, Japan.
Department of Pathology, Proteo-Science Center (PROS), Toon Shitsukawa, Ehime 791-0295, Japan.

Shigeki Higashiyama (S)

Department of Cell Growth and Tumor Regulation, Proteo-Science Center (PROS), Ehime University, Toon, Shitsukawa, Ehime 791-0295, Japan.
Department of Biochemistry and Molecular Genetics, Ehime University Graduate School of Medicine, Toon, Shitsukawa, Ehime 791-0295, Japan.
Department of Molecular and Cellular Biology, Research Center, Osaka International Cancer Institute, Chuo-ku, Osaka-shi, Osaka 541-8567, Japan.

Hironori Izutani (H)

Department of Cardiovascular and Thoracic Surgery, Ehime University Graduate School of Medicine, Toon, Shitsukawa, Ehime 791-0295, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH